French biotech company Ipsen has announced the acquisition of US-based Kartos Therapeutics for $450 million. The deal is expected to expand Ipsen’s oncology pipeline with a late-stage blood cancer treatment.
Details of the Acquisition
The acquisition gives Ipsen access to navtemadlin, an investigational oral therapy being evaluated in a Phase III trial for patients with myelofibrosis, a rare blood cancer. Kartos shareholders will be eligible for up to $1.3 billion in additional milestone payments tied to regulatory and sales targets.
Initial trial data is expected in 2027, potentially paving the way for the therapy to be launched as early as 2028. Ipsen says the acquisition will boost core operating income from 2029. The deal is expected to close by the end of the third quarter of this year, subject to antitrust clearance.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
